An interventional study of Galenic Immunonutrition Formula in Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer and Lung Cancer, sponsored by Fondazione del Piemonte per l'Oncologia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Fondazione del Piemonte per l'Oncologia · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy — 44 open to participants now, 62 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Italy.
Among the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, this one is the 89th largest by planned enrollment of the 109 interventional ones that give a count, is one of 11 that started in 2025, is one of 8 with no phase, reaches primary completion later than 30 of the 61 other live ones, and was the 126th registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →44 of the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy are open now. Recruiting first, the newest first:
Corbus Pharmaceuticals Inc. · Sites in Italy, United States, Austria and 11 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in Italy
Ages 18+
Janssen Research & Development, LLC · Sites in Italy, United States, Australia and 19 more countries
Ages 18+
Tobias Todsen · Sites in Italy, United States, Denmark and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 54 · Phase 3 36
First in 1992; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 52 is close to the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 194 across the 109 interventional studies, 135 across the 20 observational. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 129 have an industry lead sponsor. The 10 most frequent:
Fondazione del Piemonte per l'Oncologia is the lead sponsor of 39 studies on the registry; 18 are open to participants now.
Fondazione del Piemonte per l'Oncologia has 3 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
17 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05815927Phase 3European Organisation for Research and Treatment of Cancer - EORTCPembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer | 2027-07-15 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07448727University of Rome Tor VergataImpact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT | 2026-12-31 |
| NCT05621837Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoQuantifying Systemic Immunosuppression to Personalize Cancer Therapy | 2026-12-31 |
| NCT07949526IRCCS San RaffaeleCompressive Dressing and Pharyngocutaneous Fistula After Primary Total Laryngectomy | 2027-01-05 |
Add all 17 to your calendar (.ics) → With an account.
Among the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GALENOS 2 is a single-arm, single-center, phase II interventional study designed to evaluate the effects of a galenic immunonutrition dietary supplement in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer undergoing standard antineoplastic treatment. The study aims to assess whether the formula may reduce treatment-related toxicity and improve treatment compliance, using patients from the GALENOS 1 observational study as the control group for comparison
This prospective interventional study will enroll adult patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer who are candidates for standard chemoradiotherapy, chemotherapy, radiotherapy, or immunotherapy according to clinical practice. All enrolled participants will receive a galenic immunonutrition formula twice daily starting on the first day of antineoplastic treatment and continuing for up to 45 days, in addition to standard nutritional counseling and routine oncologic care. The study will prospectively assess treatment-related toxicity, nutritional status, body composition, muscle function, cytokine profiles, quality of life, physical activity, treatment adherence/tolerance, and compliance with the galenic formula. Outcomes in GALENOS 2 will be compared with matched or pooled control patients from the GALENOS 1 observational study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer undergoing standard antineoplastic treatment will receive the galenic immunonutrition formula twice daily from treatment start for a maximum of 45 days, alongside routine nutritional counseling and standard clinical management
Dietary Supplement: Galenic Immunonutrition Formula
The investigational galenic immunonutrition formula is a jelly-based oral supplement formulated with arginine, brewer's yeast, omega-3 powder, olive oil, soy lecithin, glycerol, animal gelatine, purified water, citrate components, and flavoring, with sugar-containing or sweetener-containing versions and peach or lemon flavor options. Participants will receive two servings per day starting on the first day of antineoplastic treatment and continuing for up to 45 days. The product will be prepared and supplied free of charge by the Hospital Pharmacy of FPO-IRCCS Candiolo
Participants with at least 1 Grade 3 or higher treatment-related adverse event
Number of participants with at least 1 treatment-related adverse event of Grade 3 or higher, assessed according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)
Time frame: From the first day of antineoplastic treatment to end of trial, assessed up to 63 days
Body weight
Body weight measured in kilograms (kg)
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Body mass index
Body mass index calculated as body weight in kilograms divided by height in meters squared (kg/m²)
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Daily oral energy intake
Average daily oral energy intake assessed from food record and expressed in kilocalories per day (kcal/day).
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Nutritional Risk Screening 2002 score
Nutritional risk assessed using the Nutritional Risk Screening 2002 (NRS-2002). Total score ranges from 0 to 7, with higher scores indicating greater nutritional risk and worse nutritional status
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Prognostic Nutritional Index
Prognostic Nutritional Index (PNI). Higher values indicate better nutritional and immunologic status
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Participants requiring additional nutritional support
Number of participants requiring additional oral, enteral, or parenteral nutritional support during the study period
Time frame: From the first day of treatment to end of trial, assessed up to 63 days
Skeletal muscle mass
Skeletal muscle mass measured by bioimpedance analysis and expressed in kilograms (kg)
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Fat-free mass
Fat-free mass measured by bioimpedance analysis and expressed in kilograms (kg).
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Body cell mass
Body cell mass measured by bioimpedance analysis and expressed in kilograms (kg).
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Fat mass
Fat mass measured by bioimpedance analysis and expressed in kilograms (kg).
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Total body water
Total body water measured by bioimpedance analysis and expressed in liters (L)
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Skeletal muscle index
Skeletal muscle index measured by bioimpedance analysis and expressed in kg/m²
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Phase angle
Phase angle measured by bioimpedance analysis and expressed in degrees. Higher values generally indicate better cellular integrity
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Handgrip strength
Maximum handgrip strength measured using a handgrip dynamometer and expressed in kilograms (kg).
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Handgrip endurance
Handgrip endurance measured using a handgrip dynamometer.
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
ECOG Performance Status score
Performance status assessed using the Eastern Cooperative Oncology Group (ECOG) Performance Status scale. Scores range from 0 to 5, with higher scores indicating worse functional impairment
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Toxicity-free survival
Time from the first day of antineoplastic treatment to the first documented treatment-related adverse event, assessed according to CTCAE v5.0, expressed in days
Time frame: From the first day of treatment to first toxicity or end of trial, assessed up to 63 days
Relative chemotherapy dose delivered
Total chemotherapy dose administered expressed as the percentage of the planned chemotherapy dose
Time frame: From treatment start to end of treatment, assessed up to 63 days
Relative radiotherapy dose delivered
Total radiotherapy dose administered expressed as the percentage of the planned radiotherapy dose.
Time frame: From treatment start to end of treatment, assessed up to 63 days
Relative immunotherapy dose delivered
Total immunotherapy dose administered expressed as the percentage of the planned immunotherapy dose.
Time frame: From treatment start to end of treatment, assessed up to 63 days
Relative variation in treatment duration
Variation in actual treatment duration compared with planned treatment duration, expressed as a percentage
Time frame: From treatment start to end of treatment, assessed up to 63 days
Participants completing the planned treatment schedule
Number of participants who complete the planned treatment schedule.
Time frame: From treatment start to end of treatment, assessed up to 63 days
Participants requiring unplanned hospitalization
Number of participants requiring at least 1 unplanned hospitalization during the study period.
Time frame: From treatment start to end of trial, assessed up to 63 days
EORTC QLQ-C30 Global Health Status / Quality of Life score
Self-perceived quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 version 3.0 (EORTC QLQ-C30 v3.0), Global Health Status / Quality of Life scale. Scores range from 0 to 100, with higher scores indicating better quality of life.
Time frame: At baseline (T0), during treatment, and at end of trial (T3), assessed up to 63 days
International Physical Activity Questionnaire score
Physical activity assessed using the International Physical Activity Questionnaire (IPAQ).
Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days
Formula compliance
Compliance with the galenic immunonutrition formula, expressed as the percentage of prescribed daily servings recorded as consumed in the daily intake diary.
Time frame: From the first day of treatment to Day 45, assessed up to 45 days
Change in circulating CCL2 concentration
Plasma CCL2 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating CCL4 concentration
Plasma CCL4 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating CCL22 concentration
Plasma CCL22 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating CXCL10 concentration
Plasma CXCL10 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IFN-γ concentration
Plasma IFN-γ concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-2 concentration
Plasma IL-2 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-4 concentration
Plasma IL-4 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-5 concentration
Plasma IL-5 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-6 concentration
Plasma IL-6 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-8 concentration
Plasma IL-8 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-10 concentration
Plasma IL-10 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-12 concentration
Plasma IL-12 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-13 concentration
Plasma IL-13 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating IL-15 concentration
Plasma IL-15 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating TGF-β concentration
Plasma TGF-β concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in circulating TNF-α concentration
Plasma TNF-α concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Change in C-reactive protein concentration
C-reactive protein concentration measured in peripheral blood
Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jul 2027, 21 months after the start.
Of 116 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 21 months is below that.
Counting every sponsor, half of 127 studies reached it within 59 months; a quarter within 34 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Cell Carcinoma of Head and Neck →
Fondazione del Piemonte per l'Oncologia